Mymd Pharmaceuticals (NASDAQ:QCLS) Trading 0.4% Higher – Here’s Why

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS)’s stock price was up 0.4% on Friday . The stock traded as high as $0.8964 and last traded at $0.7633. 4,407,556 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 13,221,239 shares. The stock had previously closed at $0.76.

Wall Street Analysts Forecast Growth

Several brokerages have commented on QCLS. Wall Street Zen raised Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research note on Friday, August 7th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Price Performance

The stock has a market capitalization of $6.25 million, a PE ratio of -0.22 and a beta of 2.09. The company’s 50 day moving average price is $2.48.

Mymd Pharmaceuticals (NASDAQ:QCLS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) earnings per share (EPS) for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways.

The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions.